热门出版物 - 学术资源搜索

h5 指数:34
h5 中位数:58

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#19 Nuclear Medicine, Radiotherapy & Molecular Imaging

标题/作者	引用次数	年份
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies R Pötter, K Tanderup, C Kirisits, A de Leeuw, K Kirchheiner, R Nout, ... Clinical and Translational Radiation Oncology 9, 48-60	446	2018
Adaptive radiotherapy: The Elekta Unity MR-linac concept D Winkel, GH Bol, PS Kroon, B van Asselen, SS Hackett, ... Clinical and Translational Radiation Oncology 18, 54-59	362	2019
Technical design and concept of a 0.35 T MR-Linac S Klüter Clinical and Translational Radiation Oncology 18, 98-101	245	2019
COVID-19: Global radiation oncology’s targeted response for pandemic preparedness R Simcock, TV Thomas, C Estes, AR Filippi, MS Katz, IJ Pereira, H Saeed Clinical and Translational Radiation Oncology 22, 55-68	233	2020
Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? H Mirghani, P Blanchard Clinical and Translational Radiation Oncology 8, 4-11	177	2018
Relative biological effectiveness in proton beam therapy–Current knowledge and future challenges A Lühr, C von Neubeck, M Krause, EGC Troost Clinical and Translational Radiation Oncology 9, 35-41	128	2018
Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review R Chicas-Sett, I Morales-Orue, D Rodriguez-Abreu, P Lara-Jimenez Clinical and Translational Radiation Oncology 9, 5-11	84	2018
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials L Spiegelberg, R Houben, R Niemans, D de Ruysscher, A Yaromina, ... Clinical and Translational Radiation Oncology 15, 62-69	84	2019
Spatially fractionated radiation therapy: History, present and the future W Yan, MK Khan, X Wu, CB Simone, J Fan, E Gressen, X Zhang, ... Clinical and Translational Radiation Oncology 20, 30-38	81	2020
The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts M Ansems, PN Span Clinical and Translational Radiation Oncology 22, 90-97	73	2020
4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience ES Paulson, E Ahunbay, X Chen, NJ Mickevicius, GP Chen, C Schultz, ... Clinical and Translational Radiation Oncology 23, 72-79	70	2020
Healthcare ex Machina: Are conversational agents ready for prime time in oncology? JE Bibault, B Chaix, P Nectoux, A Pienkowski, A Guillemasé, B Brouard Clinical and Translational Radiation Oncology 16, 55-59	68	2019
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours MT Dillon, Z Boylan, D Smith, J Guevara, K Mohammed, C Peckitt, ... Clinical and Translational Radiation Oncology 12, 16-20	66	2018
Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment PC Lara, J Burgos, D Macias Clinical and Translational Radiation Oncology 23, 27-29	66	2020
Learning from scanners: Bias reduction and feature correction in radiomics I Zhovannik, J Bussink, A Traverso, Z Shi, P Kalendralis, L Wee, A Dekker, ... Clinical and Translational Radiation Oncology 19, 33-38	61	2019
The rationale for MR-only treatment planning for external radiotherapy J Jonsson, T Nyholm, K Söderkvist Clinical and Translational Radiation Oncology 18, 60-65	61	2019
Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac A Dunlop, A Mitchell, A Tree, H Barnes, L Bower, J Chick, E Goodwin, ... Clinical and Translational Radiation Oncology 23, 35-42	60	2020
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status B Fulton, SC Short, A James, S Nowicki, C McBain, S Jefferies, C Kelly, ... Clinical and Translational Radiation Oncology 8, 12-16	57	2018
Prostate cancer–Advantages and disadvantages of MR-guided RT J Murray, AC Tree Clinical and Translational Radiation Oncology 18, 68-73	56	2019
Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma JK Bronk, N Guha-Thakurta, PK Allen, A Mahajan, DR Grosshans, ... Clinical and Translational Radiation Oncology 9, 30-34	53	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。